Most common treatment-related AEs with KEYTRUDA® adjuvant therapy (≥15% of patients)[1]

	KEYTRUDA® 200 mg every 3 weeks (n=509)			Placebo (n=502)		
Adverse Reaction	**Any Grade**	**Grade 3**	**Grade 4**	**Any Grade**	**Grade 3**	**Grade 4**
Diarrhea	18.5%	0.6%	0.2%	16.3%	0.6%	-
Fatigue	28.1%	0.8%	-	26.9%	0.4%	-
Pruritus	16.7%	-	-	9.8%	-	-

Adapted from the KEYTRUDA® Product Monograph.[1]